USFDA accepts application for Merck KEYTRUDA plus chemotherapy as treatment for Biliary Tract Cancer Ruchika Sharma9 Jun 2023 5:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted for review...
MSD Pharma Gets CDSCO Panel Nod for additional indication of anticancer drug Pembrolizumab Dr. Divya Colin23 May 2023 6:00 PM ISTNew Delhi: Based on the global clinical trial data presented by drug major, MSD Pharmaceuticals, the Subject Expert Committee (SEC) functional under...
Desmoplastic melanoma patients respond "exceptionally" well to treatment with immunotherapy alone Dr. Kamal Kant Kohli5 May 2023 8:00 PM ISTUSA: A recent study has suggested that many patients with desmoplastic melanoma could avoid the risk of toxicity from combination therapies and...
Pembrolizumab effective as post-nephrectomy adjuvant therapy in clear cell renal cell carcinoma: LANCET Dr.Niharika Harsha B12 April 2023 9:30 AM ISTUpdated results from the KEYNOTE-564 trial showed that pembrolizumab monotherapy can be used as a standard of care for patients with renal...
Import duty exempted on all drugs, food for special medical purposes for personal use to treat rare diseases Ruchika Sharma31 March 2023 1:03 PM ISTNew Delhi: The government has exempted basic customs duty on all drugs and food for special medical purposes imported for personal use for treatment...
Immunotherapy before surgery significantly improves outcomes of patients with melanoma: NEJM Dr. Kamal Kant Kohli10 March 2023 10:00 AM ISTUCLA Jonsson Comprehensive Cancer Center researchers have found in a multicenter trial that Immunotherapy before surgery significantly improves...
Merck scraps another prostate cancer study as Keytruda therapy disappoints Ruchika Sharma1 March 2023 2:15 PM ISTNew Delhi: Merck & Co said on Tuesday it will stop a late-stage trial evaluating a combination therapy with its cancer drug Keytruda after interim...
Wellmarker Bio enters clinical trial collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA Ruchika Sharma9 Feb 2023 2:15 PM ISTWM-A1-3389 is a novel therapeutic antibody targeting a new immune checkpoint protein discovered by Wellmarker Bio and has demonstrated efficacy across...
MSD bags DCGI nod for Keytruda to treat cervical cancer Ruchika Sharma25 Jan 2023 12:30 PM ISTMumbai: Drugs Controller General of India (DCGI) has approved Keytruda (pembrolizumab), MSD’s anti-PD-1 therapy, for the treatment of persistent,...
Drug combination for stage IV melanoma shows success in trial Dr. Kamal Kant Kohli17 Jan 2023 10:00 AM ISTA new multidrug treatment for patients with stage IV melanoma has proven effective after a three-year clinical trial at the University of Colorado...
Merck, Antengene collaborate to test Keytruda, ATG-037 combo for solid tumors in phase 1 trial Ruchika Sharma31 Dec 2022 11:30 AM ISTATG-037 is an orally available, small molecule CD73 inhibitor.
Merck secures USFDA priority review for PADCEV with KEYTRUDA for treatment of Urothelial Cancer Ruchika Sharma22 Dec 2022 3:21 PM ISTPADCEV (enfortumab vedotin-ejfv) is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface...
